3-O-Laurylglyceryl ascorbate reinforces skin barrier function through not only the reduction of oxidative stress but also the activation of ceramide synthesis.
OBJECTIVE
A higher trans-epidermal water loss (TEWL) occurs in rough skin, in elder skin and also in atopic dermatitis. An impaired skin barrier function is considered to be caused by an incomplete construction of the intercellular lamellar structure due to the quantitative reduction of ceramides. Since these symptoms coexist with oxidative stress, we hypothesized that impairment of the skin barrier function is accelerated by oxidative stress. Thus, the purpose of this study was to clarify the effect of oxidative stress on ceramide synthesis and to characterize whether antioxidants can improve skin barrier function. 3-O-Laurylglyceryl ascorbate (VC-3LG), which is a newly amphipathic derivative of ascorbic acid, was evaluated as a candidate antioxidant.


METHODS
We characterized the mRNA expression levels of serine palmitoyltransferase (SPT) in normal human epidermal keratinocytes (NHEKs) treated with H2O2using real-time PCR analysis. In order to evaluate the effect of VC-3LG on skin barrier function, we used several assays with reconstructed human epidermis equivalents (RHEEs).


RESULTS
Ceramide synthesis was down-regulated in NHEKs by oxidative stress. Treatment with VC-3LG abrogated the down-regulation of SPT mRNA in NHEKs caused by oxidative stress, and stimulated SPT mRNA expression levels. In experiments characterizing the antioxidative properties of VC-3LG, VC-3LG reduced oxidative stress in NHEKs by up-regulating catalase mRNA expression. In addition, VC-3LG stimulated the skin barrier function in RHEEs, which had lower TEWL values compared with untreated RHEEs. Furthermore, VC-3LG increased the quantity of ceramide in RHEEs.


CONCLUSIONS
Taken together, we conclude that VC-3LG reinforces the skin barrier function due to its reduction of oxidative stress and its promotion of ceramide synthesis.
Seiwa Kasei Co Ltd, 1-2-14, Nunoichicho, Higashiosaka, Osaka, 579-8004, Japan.
Y
Y
Katsuyama
Seiwa Kasei Co Ltd, 1-2-14, Nunoichicho, Higashiosaka, Osaka, 579-8004, Japan.
N
N
Taira
Seiwa Kasei Co Ltd, 1-2-14, Nunoichicho, Higashiosaka, Osaka, 579-8004, Japan.
T
T
Tsuboi
Seiwa Kasei Co Ltd, 1-2-14, Nunoichicho, Higashiosaka, Osaka, 579-8004, Japan.
M
M
Yoshioka
School of Bioscience and Biotechnology, Tokyo University of Technology, 1404-1, Katakuracho, Hachiouji, Tokyo, 192-0982, Japan.
H
H
Masaki
School of Pharmacy, Kinki University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan.
O
O
Muraoka
D000975:Antioxidants / Q000494:pharmacology; D001205:Ascorbic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D002478:Cells, Cultured; D002518:Ceramides / Q000096:biosynthesis*; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects*; D047493:PPAR alpha / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D051102:Serine C-Palmitoyltransferase / Q000235:genetics; D012869:Skin Absorption / Q000187:drug effects*; D015854:Up-Regulation
D000975:Antioxidants; D002518:Ceramides; D047493:PPAR alpha; D012333:RNA, Messenger; D051102:Serine C-Palmitoyltransferase; D001205:Ascorbic Acid
3-O-laurylglyceryl ascorbate; antioxidant; ceramide; serine palmitoyltransferase; skin barrier